Stockscreener 앱 받기
1.42
1.42%
0.01
전일 마감가:
$1.41
열려 있는:
$1.41
하루 거래량:
451.93K
Relative Volume:
0.95
시가총액:
$48.60M
수익:
-
순이익/손실:
$-69.00M
주가수익비율:
-0.5108
EPS:
-2.78
순현금흐름:
$-55.26M
1주 성능:
-7.74%
1개월 성능:
-5.30%
6개월 성능:
-81.74%
1년 성능:
-85.09%
1일 변동 폭
$1.36
$1.50
1주일 범위
$1.32
$1.55
52주 변동 폭
$1.30
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
명칭
Acrivon Therapeutics Inc
전화
617-207-8979
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.43 | 48.60M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.12 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
657.73 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.61 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.07 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-12-15 | 재개 | Jefferies | Buy |
| 2023-10-05 | 개시 | Maxim Group | Buy |
| 2023-06-02 | 개시 | Oppenheimer | Outperform |
| 2023-05-08 | 개시 | BMO Capital Markets | Outperform |
| 2023-04-27 | 개시 | Ladenburg Thalmann | Buy |
| 2023-04-20 | 개시 | H.C. Wainwright | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-12-12 | 개시 | Jefferies | Buy |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
모두보기
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Piper Sandler sets $6 target for Acrivon stock, rates it Overweight - Investing.com India
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Sold by JPMorgan Chase & Co. - Defense World
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $21.80 - Defense World
Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - Defense World
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 19.9% - Defense World
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million By Investing.com - Investing.com Canada
Major Shareholder Sells Massive Stake in Acrivon Therapeutics! - TipRanks
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com
You might want to take a look at Acrivon Therapeutics Inc (ACRV) now - Sete News
Acrivon Therapeutics Inc (ACRV)’s stock decline to 1.44 per share - uspostnews.com
Major Shareholder Sells Millions in Acrivon Therapeutics Stock! - TipRanks
ACRV’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Acrivon Therapeutics (ACRV) Sees Surge in Interest Amid Key Deve - GuruFocus
KeyBanc Capital Markets initates Acrivon Therapeutics Inc (ACRV) rating to an Overweight - knoxdaily.com
Understanding ACRV stock ratios for better investment decisions - uspostnews.com
Acrivon Therapeutics Presents Findings on ACR-2316's Mechanisms of Tumor Cell Death at AACR Annual Meeting - Nasdaq
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - GlobeNewswire
Breakthrough Cancer Drug ACR-2316 Achieves 25% Tumor Reduction with Zero Safety Issues in Phase 1 Trial - Stock Titan
(ACRV) On The My Stocks Page - news.stocktradersdaily.com
April 2025's Standout Penny Stocks - simplywall.st
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 21.4% in March - Defense World
Acrivon Therapeutics Inc’s Banking’s 100-Day Moving Average at 5.3600: Will the Stock Break Through? - investchronicle.com
ACRV’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com
Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - NewsBreak: Local News & Alerts
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment - Investing.com UK
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment By Investing.com - Investing.com South Africa
Acrivon Therapeutics’ SWOT analysis: oncology innovator’s stock faces pivotal moment - Investing.com India
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.17 Average Price Target from Analysts - Defense World
Acrivon Therapeutics Reports Progress in Cancer Drug Development - TipRanks
Acrivon Therapeutics Appoints Mansoor Raza Mirza, M.D., as Chief Medical Officer - citybiz
Acrivon appoints new chief medical officer to advance cancer trials By Investing.com - Investing.com South Africa
Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief - marketscreener.com
Acrivon appoints new chief medical officer to advance cancer trials - Investing.com
Acrivon Therapeutics Appoints New Chief Medical Officer - TipRanks
Acrivon Therapeutics Appoints World-Renowned Oncology Key - GlobeNewswire
Head-To-Head Comparison: Astellas Pharma (OTCMKTS:ALPMY) versus Acrivon Therapeutics (NASDAQ:ACRV) - The AM Reporter
Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN
Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com
HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World
FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan
Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Acrivon Therapeutics Inc (ACRV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acrivon Therapeutics Inc 주식 (ACRV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
| Devroe Eric | Chief Operating Officer |
May 17 '24 |
Option Exercise |
1.04 |
10,000 |
10,400 |
69,097 |
0.52%
0.52%
자본화:
|
볼륨(24시간):